Friday, May 1, 2026

YouTuber Sentenced for Spreading Fake News About K-Pop Star Jang Wonyoung

A YouTuber received a suspended sentence for defaming K-pop star Jang Won Young, ordered to pay 200 million won in restitution.

THE EXODUS HAS BEGUN : Why U.S. Nuclear Defense Assets Are Fleeing South Korea For The Middle East War Zone

U.S. military assets in South Korea are moving to the Middle East, following airstrikes on Iran, indicating a potential redeployment.

Seoul Brings London and New York Ferry Experts to the Table: What the Han River Bus Needs to Avoid a Subsidy Trap

Seoul Mayor Oh Se Hoon addresses challenges in Han River Bus operations, emphasizing improvement and learning from global experts.

Tag: development

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Hyundai Engineering Secures $309 Million for U.S. Solar Power Plant Project in Texas

Hyundai Engineering secures $309M for Texas solar project, aiming for 200MW capacity and commercial operations by 2027.

Daewoong Pharmaceutical and Primind’s Strategic Investment in American Biotech General Proximity

Daewoong Pharmaceutical invests in biotech firms to enhance drug development using Induced Proximity technology and expand globally.

MSD Korea Announced at Bio Korea 2026 that Korea is a Crucial Hub for Global Innovation

Korea is now a key innovation hub for MSD, focusing on neuroscience and clinical research collaborations, with significant R&D investments.

Discover the Breakthroughs of Korea’s ARPA-H Project: 5 Key Missions for Health Security and Innovation

The K-Health Future Promotion Team showcased interim results of the Korean ARPA-H project at Bio Korea 2026, focusing on innovative healthcare solutions.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

HK inno.N partners with Atomatrix to co-develop AI-based next-generation obesity drug

HK inno.N partners with Atomatrix to develop AI-driven obesity treatments, focusing on novel small-molecule candidates.

Global AI Driven Rare Disease Diagnostics Firm 3Billion Enters the U.S. Insurance Market

3Billion is expanding globally, entering the U.S. insurance market, enhancing diagnostics, and pursuing drug development for growth.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

Ulsan selected for “AI ship specialized platform” project…secures $140 million in government funding

Ulsan City secures $140M for an AI ship platform project, enhancing navigation and efficiency through software-driven technology.

Alzheimer’s Breakthrough: Monthly Injections of IVL3003 vs. GB-5001A—Which is More Effective?

New long-acting injectable formulations of donepezil for Alzheimer's aim to improve adherence and efficacy, easing caregiver burdens.

Naver to remove Chinese components from AI models, fully adopt in-house vision encoder

Naver will replace its controversial Chinese vision encoder with a self-developed one to enhance its AI models for Korean language and culture.

YH35995: A Game-Changer for Gaucher Disease? FDA Grants Orphan Drug Designation

Yuhan Corp's YH35995 for Gaucher disease receives orphan drug designation, enhancing its development for rare diseases with unmet needs.

Samjin Pharmaceutical and Ewha Womans University Seoul Hospital Sign MOU for Innovative Migraine Treatment

Samjin Pharmaceutical partners with Ewha Womans University Medical Center to develop treatments for CNS disorders, focusing on migraines.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.